1 January 2022 in S.S. Korsakov Journal of Neurology and Psychiatry
Астения представляет собой клинический синдром, которым могут проявляться практически все соматические, инфекционные и неврологические заболевания. Исходно являясь защитным механизмом, свидетельствующим об истощении энергетических ресурсов, астения может становиться патологическим, крайне инвалидизирующим состоянием и даже переходить в самостоятельную форму иммунно-опосредованного заболевания — синдром хронической усталости. Астения часто сочетается с аффективными и когнитивными расстройствами, что вызывает трудности диагностики. В статье рассматриваются сложные переплетения астении, синдрома хронической усталости, когнитивных и аффективных расстройств.
23 January 2024 in S.S. Korsakov Journal of Neurology and Psychiatry
Objective. To compare the content of β-amyloid (Aβ) peptides Aβ40, Aβ42, total and threonine phosphorylated 181 tau-protein in cerebrospinal fluid (CSF) of patients with the clinical diagnosis of Alzheimer’s disease (AD). Material and methods. The study was performed on 64 patients with a diagnosis of dementia and MMSE scores of 24 or lower. All patients underwent lumbar puncture. Aβ40, Aβ42, Aβ42/40 ratio, total tau, phosphorylated tau at threonine 181 were determined in the CSF using a multiplex assay according to the manufacturer’s protocol, the concentration was determined in pkg/ml. Results. The preliminary diagnosis of AD was made in 3 patients (5%). As a result of the study of protein content in the CSF, signs of AD were detected in 48 (75%) people. The findings suggest that the diagnosis of AD is made 10—14 times less frequently than it should be according to the World Health Organization data. The discrepancy between clinical diagnosis and laboratory findings is confirmed by our study. Conclusion. Differences in the therapy of dementias and the development of new drugs targeting specific links in the pathogenesis of different types of dementias require accurate and complete diagnosis of dementias, especially AD, as the most common type of dementia.
24 July 2023 in Meditsinskiy sovet = Medical Council
Affective disorders represent an extremely topical issue in modern healthcare. Prevalence of anxiety disorders in clinical practice increased significantly since 2019 due to various situational causes, and the trend will probably continue in the coming years. Besides, due to aging of the population and significant growth of the number of patients with neurodegenerative diseases, so called secondary affective disorders also increase. These are linked to organic lesion of the zones strategically important for emotional process implementation, and damaging of the key neurotransmitter systems neurons often seen in neurodegenerative pathological process. Development of anxiety is chiefly based on the defect of the “threat-fear” bound, with the reaction developing in the organism not equivalent to the degree of danger. On pathophysiological level this can be explained by disruption of interaction between limbic system structures that provide “fight or flight” reflex response to the threat, and the neocortex responsible for cognitive processing and adaptation of out emotional reactions. Three key theories of anxiety development can be identified: insufficiency of control, generalization of fear, and hypersensibilization to threat. The first mechanism is most often linked to development of generalized anxiety disorder, the second theory reveals most fully the mechanisms of post-traumatic stress disorder development, while the hypersensibilization of prefrontal cortex best allows to explain sociophobia development. An important mechanism of development and chronification of various affective disorders is neuroinflammation, the role of which will also be highlighted in detail in this review. Understanding of the mechanisms of anxiety spectrum disorders development is important for differentiated drug and non-drug therapy and establishing the optimal strategy of treatment for such patients.
12 March 2022 in Meditsinskiy sovet = Medical Council
Dopamine receptor agonists (DRA) are a class of therapeutic drugs able to directly stimulate dopaminergic receptors facilitating a stronger effect of the endogenous dopamine, which is widely used in treatment of diseases that are accompanied with dopaminergic neurotransmission deficiency. A classical hypodopaminergic condition is Parkinson’s disease and DRA are traditionally associated with it. However, even the first DRA, Bromocriptine, widely adopted in PD treatment, was initially registered as a medication for treatment of prolactinaemia and associated pituitary adenomas and is still widely used in gynecology and endocrinology. In several countries DRA are used in treatment of diabetes, eating disorders, and addictions. Dopamine is the cardinal neurotransmitter of the emotional control and the main neurotransmitter of the reward system, and that defines the interest for researching the dopaminergic agents in treatment of primarily mental illnesses, as well as correction of secondary affective disorders. The experimental effectiveness of ADR in slowing down the rate of progression of the neurodegenerative process in severe incurable diseases, as well as potential neuroprotection in cerebrovascular insufficiency, will allow in the future to determine the criteria for the use of ADR in these non-standard situations, which may even lead to a change in clinical recommendations for the treatment of individual nosologies. Presented in this article are both traditional uses of DRA and an overview of non-standard applications of this class of medications with a discussion of recent studies. In the future, the likelihood of a rethinking of ADRs as a class of only antiparkinsonian drugs, with the expansion of their therapeutic indications.
29 April 2026 in S.S. Korsakov Journal of Neurology and Psychiatry
Objective. To assess the prevalence of the transitional cognitive syndrome (TCS) and evaluate the effectiveness of neurocognitive training in elderly individuals presenting with cognitive symptoms. Material and methods. The study enrolled 198 elderly individuals with cognitive impairment symptoms from the Memory Clinics of the Moscow Department of Health and the N.A. Alekseev Psychiatric Clinical Hospital No. 1. Of these, 111 participants were assigned to the intervention group and received neurocognitive training (rehabilitation), while 87 participants formed the comparison group and received follow-up only. Neuropsychological assessments were conducted at baseline and after 12 months of follow-up. Results. In this sample, TCS accounted for approximately 5% of all cognitive impairments and remained stable over the one-year follow-up period. Annually, about 7% of mild cognitive impairment cases progressed to TCS, while 11—16% of TCS cases advanced to more severe dementia, irrespective of neurorehabilitation. These findings suggest the presence of an active neurodegenerative process. Neurorehabilitation was effective in improving regulatory functions, including among elderly participants. Conclusion. The introduction of the TCS concept allows for more precise classification of patients at the transitional stage between mild cognitive impairment and dementia. This framework improves risk assessment for short-term progression to more severe cognitive impairment and provides clinical justification for pathogenetic therapy, including the use of Miladean. The TCS concept also supports patient management and reduces the stigma associated with diagnosis at this stage, which is significant for both patients and their families. Advanced age and concomitant diabetes mellitus were identified as the most significant adverse factors for cognitive impairment. The observed effectiveness of neurocognitive rehabilitation in patients aged 75 years and older indicates that rehabilitation should not be limited by age.